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Abstract: Limited information exists regarding measurement, reproducibility and 
interrelationships of non-invasive biomarkers in smokers. We compared exhaled breath 
condensate (EBC) leukotriene B4 (LTB4) and 8-isoprostane, exhaled nitric oxide, induced 
sputum, spirometry, plethysmography, impulse oscillometry and methacholine reactivity in 
18 smokers and 10 non-smokers. We assessed the relationships between these measurements 
and within-subject reproducibility of EBC biomarkers in smokers. Compared to non-smokers, 
smokers had signiﬁ  cantly lower MMEF % predicted (mean 64.1 vs 77.7, p = 0.003), FEV1/FVC 
(mean 76.2 vs 79.8 p = 0.05), speciﬁ  c conductance (geometric mean 1.2 vs 1.6, p = 0.02), higher 
resonant frequency (mean 15.5 vs 9.9, p = 0.01) and higher EBC 8-isoprostane (geometric 
mean 49.9 vs 8.9 pg/ml p = 0.001). Median EBC pH values were similar, but a subgroup of 
smokers had airway acidiﬁ  cation (pH   7.2) not observed in non-smokers. Smokers had 
predominant sputum neutrophilia (mean 68.5%). Repeated EBC measurements showed 
no signiﬁ  cant differences between group means, but Bland Altman analysis showed large 
individual variability. EBC 8-isoprostane correlated with EBC LTB4 (r = 0.78, p = 0.0001). 
Sputum supernatant IL-8 correlated with total neutrophil count per gram of sputum (r = 0.52, 
p = 0.04) and with EBC pH (r = −0.59, p = 0.02). In conclusion, smokers had evidence of 
small airway dysfunction, increased airway resistance, reduced lung compliance, airway 
neutrophilia and oxidative stress.
Keywords: smoking, exhaled breath condensate, exhaled nitric oxide, induced sputum, respi-
ratory function tests
Introduction
Cigarette smoking is the major risk factor for the development of chronic obstruc-
tive pulmonary disease (COPD). Smokers without COPD have evidence of airway 
inﬂ  ammation, small airway dysfunction and bronchial hyperreactivity (Cosio et al 
1978; Tashkin et al 1996; Stanescu et al 1998; Clark et al 2001; Saetta et al 2001). 
In a proportion of cases, these pathophysiological abnormalities become ampliﬁ  ed, 
causing airﬂ  ow obstruction. The early pathophysiological changes caused by smoking 
therefore form an integral part of the study of COPD.
Spirometry is routinely used to diagnose COPD. Alternative pulmonary function 
methods such as body plethysmography, which measures lung volumes and airway 
conductance, and impulse oscillometry (IOS), which measures pulmonary resistance 
and compliance, provide valuable additional information on pulmonary dynamics. 
Using these additional methods may provide evidence of the early physiological 
abnormalities present in smokers without airﬂ  ow obstruction ie, with normal forced 
expiratory volume in 1 second (FEV1).
Non-invasive techniques such as induced sputum, exhaled breath condensate (EBC) 
and exhaled nitric oxide (NO) are being increasingly used to identify biomarkers that are 
linked to the effects of smoking and the development of airﬂ  ow obstruction. Although International Journal of COPD 2008:3(1) 172
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bronchial biopsy remains the gold standard investigation of 
airway inﬂ  ammation, these techniques have the beneﬁ  t of 
being non-invasive, safe and easily repeatable. There is evi-
dence that smokers without COPD have sputum neutrophilia 
(Pizzicini et al 1996; Chalmers et al 2001; Rytila et al 2006), 
increased EBC 8-isoprostane (Montuschi et al 2000) and 
reduced exhaled NO (Kharitonov et al 1995; Corradi et al 
1999; Malinovschi et al 2006; Rytila et al 2006). Although 
EBC pH is known to be reduced in COPD patients (Kostikas 
et al 2002), this has not been studied in smokers.
Induced sputum, EBC and exhaled NO measurements 
have not been investigated during the same study in smokers, 
so it is not known whether these measurements are indepen-
dent or related variables in this population group. Induced 
sputum, EBC and exhaled gas analysis all sample different 
compartments of the airways by different methods, and can 
be used to analyze different biological mediators that are 
involved in a range of inﬂ  ammatory processes. For this reason, 
it is important to understand whether biomarkers measured 
by these techniques provide similar or different information 
about airway inﬂ  ammation. For example, it is not known 
if airway neutrophilia is related to increased 8-isoprostane 
production or airway acidiﬁ  cation in smokers.
EBC measurements can be prone to signiﬁ  cant variability 
(Horvath et al 2005). Although studies have shown raised 
levels of EBC 8 isoprostane and LTB4 in smokers (Montuschi 
et al 2000; Carpagnano et al 2003), there have been concerns 
about the reproducibility of these assays (van Hoydonck et al 
2004; Borrill et al 2005; Rahman 2005).
We report a comprehensive assessment of non-invasive bio-
markers of airway inﬂ  ammation (EBC, exhaled NO and induced 
sputum), bronchial hyperreactivity (BHR) and lung function (spi-
rometry, plethysmography and IOS) in smokers without airﬂ  ow 
obstruction. The primary aims of this study were 1) to compare 
pulmonary function and non-invasive biomarker data between 
smokers and non-smokers to gain a comprehensive understand-
ing of the early physiological and inﬂ  ammatory effects of ciga-
rette smoking, and 2) to investigate the relationships between 
non-invasive biomarkers in smokers. We also investigated the 
reproducibility of EBC biomarkers in smokers.
Methods
Subjects and study design
18 current smokers (mean age 46.4 [SD 9.6], 7 male, mean 
pack years 25.5 [SD 10.3]) and 10 lifelong non-smoking 
healthy controls (mean age 44.8 [SD 15.6], 4 male) with 
normal lung function were recruited. Exclusion criteria 
were; history of asthma or atopy, FEV1  85% predicted, 
FEV1/FVC  70%, respiratory tract infection within 2 weeks, 
any concomitant medication or major concurrent medical 
condition. Subjects were asked to avoid caffeine and cigarettes 
for 2 hours prior to each visit. Written informed consent was 
obtained and the study was approved by the South Manchester 
Medical Research Ethics Committee, Gateway House, 
Piccadilly South, Manchester, UK. The study was conducted 
in accordance with the Declaration of Helsinki of 1975.
Subjects underwent EBC, exhaled NO, respiratory 
function tests (IOS, plethysmography and spirometry), 
methacholine challenge and induced sputum assessments 
in that order (visit 1). One week later, all smokers attended 
for repeated EBC (visit 2). EBC samples were obtained 
from all subjects, and were used ﬁ  rstly for 8-isoprostane and 
LTB4 analysis. After 8-isoprostane and LTB4 analysis there 
was sufﬁ  cient sample remaining for pH analysis in all non-
smokers, 17 smokers at visit 1, and 14 at visit 2. Adequate 
sputum samples were obtained from 16 smokers but only 2 
non-smokers. Non-smokers’ sputum data was not used fur-
ther. Methacholine challenge was performed in 15 smokers 
and all non-smokers. The relationship between non-invasive 
biomarkers was assessed in smokers at visit 1.
Pulmonary function and methacholine 
challenge
For IOS (Masterscreen IOS, Erich Jaeger, Hoechberg, 
Germany) subjects supported their cheeks to reduce upper 
airway shunting while impulses were applied during tidal 
breathing for 30 seconds. R5 and R20 (respiratory resistance 
at 5 and 20Hz respectively), X5 (reactance at 5 Hz) and RF 
(resonant frequency) were recorded. Airways resistance 
(Raw), speciﬁ  c conductance (sGaw), functional residual 
capacity (FRC), vital capacity (VC), inspiratory capacity 
(IC), total lung capacity (TLC) and residual volume (RV) 
were measured in a constant volume plethysmograph (Vmax 
6200, Sensormedics, Bilthoven, Netherlands). IOS and body 
plethysmograph measurements were performed in triplicate 
and the mean calculated. Maximum expiratory ﬂ  ow volume 
measurements (FEV1, forced expiratory volume in one 
second, FVC, forced vital capacity and MMEF, maximum 
mean expiratory ﬂ  ow) were performed using a spirometer 
(Super Spiro, Micromedical, Rochester, UK). Readings were 
performed in triplicate, with the highest measurement used.
Methacholine challenge was performed using a previously 
described method (Langley et al 2002). A DeVilbiss 646 
nebuliser (Sunrise medical, Wollaston, UK) and a Rosenthal 
dosimeter (PDS research, Gravesend, UK) were used to deliver 
doubling doses of methacholine, administered using 3 stock International Journal of COPD 2008:3(1) 173
Non-invasive biomarkers and lung function in smokers
concentrations (1.5 mg/ml, 12 mg/ml and 50 mg/ml; Stockport 
pharmaceuticals, Stockport, UK). FEV1 measurements were 
made immediately before the challenge procedure, one minute 
after the administration of saline and one minute after each 
dose of methacholine. Doubling doses of methacholine start-
ing at 0.015 mg were administered until a fall of  20% from 
the post-saline FEV1 was observed or the maximum dose of 
methacholine (5.96 mg) had been administered.
Exhaled breath condensate
EBC was collected during tidal breathing for 10 minutes 
(EcoScreen, Jaeger, Hoechberg, Germany) without a nose 
peg as previously described (Borrill et al 2005). Samples were 
aliquoted into separate 200 µl tubes and frozen at −80 ºC for 
later analysis. Argon gas was passed over the sample at 
2L/min for 10 minutes to achieve gas standardisation, after 
which pH was measured using pH 210 meter (Hanna 
instruments, Bedfordshire, UK) with a Biotrode electrode 
(Hamilton, Nevada, US). LTB4 and 8-isoprostane were 
measured by enzyme immunoassays (Cayman Chemical, 
Ann Arbour, MI, USA). All samples were analysed in 
triplicate. The lower limits of detection were 13 pg/ml and 
5 pg/ml for LTB4 and 8-isoprostane respectively.
Exhaled nitric oxide
Exhaled nitric oxide was measured using a chemiluminescence 
analyser according to the ATS guidelines (American Thoracic 
Society 1999). The results from 5 different ﬂ  ow rates (10, 30, 
50, 100 and 200 ml/s) were applied to one non-linear (Silkoff 
et al 2000) and two mixed linear and non-linear mathemati-
cal models (Pietropaoli et al 1999; Hogman et al 2002) with 
the following unknown variables; CawNO (concentration of 
NO in the airway wall), CalvNO (alveolar concentration) and 
DawNO (diffusing capacity of NO from the airway wall). 
Total maximal airway wall NO ﬂ  ux (J’awNO in pl/s) was also 
calculated as the product of CawNO and DawNO.
Induced sputum
Sputum was induced and processed as previously described 
(Pizzicini et al 1996). Brieﬂ  y, sputum was induced using 3%, 
4%, and 5% saline, inhaled in sequence for 5 min each via an 
ultrasonic nebulizer (Ultraneb 2000, Medix, Harlow, UK) 20 
minutes after 200 mcg inhaled salbutamol. Once expectorated, 
the sputum was stored on ice and processed within 1 hour. 
Sputum was selected from saliva and treated by adding four 
volumes of 0.1% dithiothreitol, followed by four volumes 
of phosphate buffered saline (Sigma, St Louis, MO, USA). 
The suspension was then ﬁ  ltered through 48 mcm nylon 
gauze (Sefar, Bury, UK) and centrifuged at 2000 rpm for 10 
minutes. The resulting supernatant was stored at −80 ºC for 
later analysis. Total leukocyte count and evaluation of cell 
viability (trypan blue exclusion method) was made and the 
cell suspension adjusted to 1.0 × 106/ml. Cytospin preparations 
were made with 50 mcl and 100 mcl of the cell suspension 
(Cytospin 4, Shandon, Runcorn, UK) after which slides were 
air dried, ﬁ  xed with methanol and stained with Rapi-diff 
(Triangle, Skelmersdale, UK). Four hundred leukocytes were 
counted and the results expressed as a percentage of the total 
leukocyte count. Supernatant IL-8 was measured using a 
commercially available quantitative enzyme linked sandwich 
immunoassay (ELISA, R&D Systems Europe, Oxon, UK) 
with a lower limit of detection of 15.625 pg/ml.
Statistical analysis
PD20, sGaw, EBC 8-isoprostane, EBC LTB4, percentage 
eosinophil count, percentage lymphocyte count and absolute 
cell counts were normally distributed after natural log trans-
formation and are expressed as geometric mean (SD). EBC 
pH data were not normally distributed and are expressed as 
median (range). All other data including supernatant IL-8, 
percentage neutrophil and macrophage counts were normally 
distributed and expressed as mean (SD). Parametric data and 
natural log transformed data were compared using unpaired 
t tests, and correlated using Pearson’s correlations. EBC pH 
data were compared using Mann-Whitney U test and corre-
lated with other non-invasive biomarkers using Spearman’s 
correlations. Signiﬁ  cance was deﬁ  ned as a p value of  0.05. 
Subjects who did not react to the highest dose of methacho-
line were assigned a PD20 of 11.92 mg (2 × maximum dose). 
Between day variability in smokers was analysed using the 
Bland Altman method expressed as mean difference and 
limits of agreement (Bland and Altman 1986).
Results
Comparison of smokers 
and non-smokers
Lung function
As a group, smokers had signiﬁ  cantly lower MMEF and 
sGaw, and signiﬁ  cantly higher RF compared to non-smokers 
(Figure 1, Table 1). FEV1/FVC was not quite signiﬁ  cantly lower 
in smokers compared to non-smokers (p = 0.05) (Table 1).
Methacholine challenge
A numerically higher proportion of smokers reacted to 
methacholine (ie, PD20 of 5.96 mg or less) compared International Journal of COPD 2008:3(1) 174
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Figure 1 (A) Natural log (Ln) sGaw in non-smokers and smokers. Non-smokers (n = 10) and smokers (n = 18). Bars represent geometric means, t test used for compari-
son. (B) Resonant frequency (RF) in non-smokers and smokers. Non-smokers (n = 10) and smokers (n = 18). Bars represent means, t test used for comparison.International Journal of COPD 2008:3(1) 175
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Table 1 Pulmonary function, bronchial hyperreactivity, exhaled breath condensate and exhaled nitric oxide results in smokers and 
non-smokers
 Smokers  Non-smokers  p  value
 (n  = 18)d (n  = 10) 
FEV1 (% predicted)a  98.2 (8.5)  104.7 (14.1)  0.23
FEV1/FVC (%)a  76.2 (4.0)  79.8 (5.2)  0.05
MMEF (% predicted)a  64.1 (8.3)  77.7 (14.1)  0.003
R5 (kPaL–1s)a  0.39 (0.17)  0.37 (0.07)  0.63
R20 (kPaL–1s)a  0.31 (0.12)  0.35 (0.07)  0.34
X5 (kPaL–1s)a  0.11 (0.05)  0.11 (0.03)  0.86
RF (Hz)a  15.5 (6.3)  9.9 (1.38)  0.02
sGaw (kPaL–1s–1)b  1.19 (1.36)  1.57 (1.20)  0.01
Raw (kPaL–1s)a  0.24 (0.08)  0.19 (0.06)  0.12
TLC (% predicted)a  106.1 (13.5)  98.8 (4.9)  0.11
FRC (% predicted)a  109.3 (29.8)  103.3 (13.5)  0.55
RV (% predicted)a  120.2 (36.6)  104.5 (23.07)  0.23
PD20 (mg)b  2.86 (5.09)  8.15 (1.86)  0.07
FeNO at 50 ml/sec(ppb)b  12.55 (5.62)  15.71 (9.81)   0.68
CawNO (ppb)b  58.88 (1.93)  73.26 (2.30)  0.45
CalvNO (ppb)b  3.56 (1.50)  2.92 (1.63)  0.26
DawNO (pl/ppb/s)b  7.40 (2.37)  7.87 (2.37)  0.85
J’awNO (pl/s)b  436.0 (2.5)  576.4 (1.8)  0.40
EBC pHc  7.16 (4.82–7.82)  7.39 (7.29–7.75)  0.18
EBC 8-isoprostane (pg/ml)b  49.9 (2.9)  8.9 (4.0)  0.001
EBC LTB4 (pg/ml)b  32.7 (3.1)  23.0 (1.7)  0.80
aMean (SD), t test.
bGeometric mean (SD), t test.
cMedian (range), Mann-Whitney U test.
dn = 18 except PD20 n = 15 and EBC pH n = 17.
CawNO (concentration of NO in the airway wall), CalvNO (alveolar concentration), DawNO (diffusing capacity of NO from the airway wall) and J’awNO (total maximal 
airway wall NO ﬂ  ux; the product of CawNO and DawNO).
to non-smokers (60% versus 30%) with a trend towards 
increased BHR in smokers that did not reach statistical sig-
niﬁ  cance (p = 0.07) (Figure 2, Table 1).
Exhaled breath condensate
8-isoprostane was signiﬁ  cantly higher in smokers compared 
to non-smokers (Figure 3A, Table 1). In contrast, levels 
of LTB4 did not differ between the 2 groups (Table 1). 
There was no statistical difference between the median 
values of EBC pH in smokers and non-smokers (Figure 3B, 
Table 1). However, there was evidence of airway acidiﬁ  cation 
in some smokers; 5 smokers had very acidic EBC pH (less 
than 6). In contrast, the pH values in all non-smokers were 
greater than 7.2. While the within subject mean differences 
in EBC biomarkers was small and statistically insigniﬁ  cant 
(p   0.05 for all comparisons), Bland Altman analysis 
revealed wide limits of agreement indicating marked between 
day variability in some individuals (Figure 4).
Exhaled NO
FeNO at 50 ml/s and non-linear model derived parameters 
using multiple ﬂ  ow rates did not differ between the 2 groups 
(Table 1). Similarly, data derived using two other NO models 
did not differ between smokers and non-smokers (data not 
shown).
Induced sputum
The predominant cell type in smokers was neutrophils. 
Mean (SD) percentage neutrophil and macrophage 
count were 68.5% (18.8) and 30.4% (18.8) respectively. 
Geometric mean percentage eosinophil count and 
lymphocyte count (SD) were 0.51 (2.54), and 0.35 (2.31) 
respectively. Geometric mean (SD) total cell, neutrophil 
and macrophage count per gram of selected sputum 
were 1.2 (2.6) × 106, 0.8 (3.1) × 106 and 0.3 (2.6) × 106 
respectively. Mean (SD) supernatant IL-8 concentration 
was 322.5 (154.7) pg/ml.
Correlations between non-invasive inﬂ  ammatory 
markers in smokers
There was a significant correlation between EBC 
8-isoprostane and LTB4 (r = 0.78, p   0.0001) in smokers 
(Figure 5a, Table 2). However, 8-isoprostane and LTB4 
did not correlate with sputum neutrophilia or with any International Journal of COPD 2008:3(1) 176
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Figure 2  Natural log (Ln) methacholine challenge PD20 in non-smokers and smokers. Non-smokers (n = 10) and smokers (n = 15). Bars represent geometric means, t test 
used for comparison.
Table 2 Correlations between non-invasive biomarkers. Data are Spearman’s correlations for EBC pH data and Pearson’s correla-
tions for all other data
  Ln EBC  Ln EBC  Supernatant  Ln TCC/g  Ln Total 
 8-isoprostane  LTB4 IL-8  (pg/ml)    neutrophil 
        count
pH n  = 17  n = 17  n = 15  n = 14  n = 14
 R  = –0.07 R  = 0.32  R = –0.59 R  = –0.18 R  = –0.17
 p  = 0.79  p = 0.21  p = 0.02 p  = 0.54  p = 0.56
Ln EBC    n = 18  n = 16  n =15 n  = 15
8-isoprostane   R = 0.78 R  = 0.33  R = 0.45  R = 0.39
   p = 0.0001 p  = 0.21  p = 0.09  p = 0.16
Ln EBC      n = 16  n = 15  n = 15
LTB4     R  = 0.19  R = 0.30  R = 0.25
     p  = 0.47  p = 0.28  p = 0.38
Supernatant       n  = 15  n = 15
IL-8 (pg/ml)        R = 0.54  R = 0.59
      p = 0.04  p = 0.02
other measurements (p   0.05 for all comparisons, 
Table 2). Sputum supernatant IL-8 correlated significantly 
with EBC pH (r = −0.59, p = 0.02 Figure 5b, Table 2), 
total neutrophil count per gram of sputum (r = 0.59, 
p = 0.02, Figure 5c, Table 2) and total cell count per 
gram of sputum (0.54, p = 0.04, Table 2). Exhaled 
NO (including model derived parameters) showed no 
significant correlations with the other measurements 
(p   0.05 for all comparisons, data not shown).
Discussion
The major ﬁ  ndings of this study were that the sensitive techniques 
of plethysmography and IOS showed the detrimental effects 
of smoking even while FEV1 was normal, and that smokers International Journal of COPD 2008:3(1) 177
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Figure 3 (A) Natural log (Ln) exhaled breath condensate 8-isoprostane concentration in non-smokers and smokers. Non-smokers (n = 10) and smokers (n = 18). Bars 
indicate geometric mean values, t test used for comparison. (B) Exhaled breath condensate pH in non-smokers and smokers. Non-smokers (n = 10) and smokers (n = 17). 
Bars indicate median values, Mann-Whitney U test used for comparison.International Journal of COPD 2008:3(1) 178
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Figure 4 (A) Bland Altman plot of EBC pH reproducibility between visit 1 and visit 2 (n = 14). (B) Bland Altman plot of EBC 8-isoprostane reproducibility between visit 1 
and visit 2 (n = 18). (C) Bland Altman plot of EBC LTB4 reproducibility between visit 1 and visit 2 (n = 18).
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had raised EBC 8-isoprostane and sputum neutrophilia, while 
a proportion had acidiﬁ  ed airway pH. Reduced EBC pH has 
been reported in established COPD (Kostikas et al 2002) but 
this is the ﬁ  rst study to demonstrate acidiﬁ  cation of EBC in 
smokers without COPD. The signiﬁ  cant association between 
sputum IL-8 and EBC pH is suggestive of links between airway 
acidity and airway inﬂ  ammation in smokers. We also observed 
considerable variability in EBC measurements. These key 
ﬁ  ndings are now discussed in more detail.
Comparison of smokers 
and non-smokers
Smokers with normal lung function are known to have 
increased mucosal inﬂ  ammation, mucus hypersecretion and 
pathological changes typical of early emphysema (Clark et al 
2001; Saetta et al 2001). The current study suggests that these 
pathological abnormalities lead to reduced MMEF, reduced 
sGaw and increased RF. The spirometric abnormalities 
observed in the current study have been previously reported 
(Clark et al 2001; D’Ippolito et al 2001). To our knowledge, 
this is the ﬁ  rst study to also use body plethysmography and 
IOS. There is published oscillometry evidence (using a forced 
random noise generator) that smokers have abnormal RF20 
(Hayes et al 1979). Abnormalities of MMEF and RF may 
be due to peripheral airway dysfunction (Cosio et al 1978; 
Bouaziz et al 1996; Kaczka et al 1999). We also observed 
reduced sGaw in smokers, indicating that the decreased 
airway conductance found in COPD patients (Mitchell et al 
1967) is also present in smokers. Overall, these ﬁ  ndings 
demonstrate that in smokers with normal FEV1 there is 
small airway dysfunction, decreased airway conductance 
and reduced lung compliance.
A numerically higher number of smokers had metha-
choline hyperreactivity compared to non-smokers, although 
there was no difference between the group PD20 mean 
values. This may have been due to insufﬁ  cient sample 
size. Nevertheless, our results show that bronchial hyper-
reactivity is present is some smokers, and previous data 
indicates that these subjects may be at increased risk of 
COPD (Tashkin et al 1996).
Acidified EBC pH has been reported in established 
COPD (Kostikas et al 2002) but there are no reports of 
EBC pH in smokers without COPD. We found that several 
smokers had very acidic EBC pH (  6), a phenomenon 
observed in COPD but not in non-smokers (Borrill et al 
2005, 2006). Although the median pH values of smokers and 
non-smokers were not statistically different, it is clear that 
a subgroup of smokers have acidic airway pH. The reasons 
for this ﬁ  nding are unclear. It has previously been reported 
that airway acidiﬁ  cation is related to bacterial colonisation 
in bronchiectasis and to neutrophilic inflammation and 
oxidative stress in COPD (Kostikas et al 2002). This study 
provides supporting evidence to suggest a link between 
neutrophilic inﬂ  ammation and airway acidity, demonstrating 
a correlation between sputum supernatant IL-8 and EBC 
pH. Cigarette smoke contains substances capable of causing 
oxidative stress and cellular toxicity (McNee and Rahman 
2001). These properties alter airway cell function, increasing 
levels of airway inﬂ  ammation in smokers. Such altered cell 
function may also lead to airway acidiﬁ  cation, either due to 
increased acid production, or decreased buffering capacity. 
Further work is needed to elucidate the reasons for and 
importance of airway acidiﬁ  cation in smokers.
We observed increased levels of the oxidative stress 
biomarker EBC 8-isoprostane in smokers compared to non-
smokers in agreement with a previous report (Montuschi 
et al 2000). This was demonstrated despite the recent obser-
vation that use of the EcoScreen results in lower levels of 
8-isoprostane than other condenser coatings (Rosias et al 
2006). However, we found no difference in EBC LTB4 
between smokers and controls. This is in contrast to a previous 
study using the same immunoassay method; while LTB4 levels 
were higher in smokers compared to non-smokers, it should 
be noted that the levels reported were much lower compared 
to the current study (Montuschi et al 2003). Furthermore, 
recent work has suggested that LTB4 present in EBC is mainly 
due to salivary contamination (Gaber et al 2006). Analysis of 
inﬂ  ammatory markers in EBC has not been standardized, and 
reported levels of LTB4 and 8-isoprostane vary (Montuschi 
et al 2000; Kostikas et al 2003; Montushci et al 2003; van 
Hoydonck et al 2004). Alternative methods such as mass 
spectrometry may improve variability and sensitivity (Cap 
et al 2004; Montuschi et al 2004).
Previous studies have shown reduced FeNO in smokers 
compared to non-smokers (Kharitonov et al 1995; Corradi et al 
1999; Rytila et al 2006), probably through inhibition of nitric 
oxide synthase activity (Hoyt et al 2003). However, increased 
numbers of inducible nitric oxide synthase positive cells have 
also been observed in sputum from smokers compared to non-
smokers (Rytila et al 2006). In the current study there was no 
difference in FeNO between smokers and non-smokers, and 
no reduction in the bronchial wall concentration of NO in 
smokers in contrast to previous studies (Hogman et al 2002; 
Malinovschi et al 2006). Levels of exhaled NO in smokers are 
determined by the balance between inhibition of nitric oxide 
synthase activity caused by smoking and upregulation of this International Journal of COPD 2008:3(1) 180
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enzyme caused by inﬂ  ammation, as well as NO consumption 
which may be affected by a variety of factors including the 
levels of reactive oxygen species (Ichinose et al 2000) and 
the degree of bacterial colonization (Gaston et al 2002). We 
speculate that the smokers in the current study had levels of 
airway inﬂ  ammation that counter-balanced the inhibitory 
effect of smoking on exhaled NO levels.
We were unable to obtain induced sputum specimens 
from the majority of healthy non-smokers in this study. 
However, it is known that macrophages are the predominant 
cell type in induced sputum from healthy non-smokers 
(Belda et al 2000). In contrast, smokers in this study had 
predominant neutrophilia. Pizzichini et al showed a trend 
towards increased neutrophilia in smokers with non-
obstructive chronic bronchitis and predominant neutrophilia 
in established COPD (Pizzichini et al 1996). Studies have 
also observed increased neutrophilia in smokers with 
normal FEV1 compared to non-smokers (Chalmers et al 
2001; Rytila et al 2006). Neutrophils play a key role in 
innate immunity, and it is clear that an abnormal innate 
immune response is present in the airways of smokers with 
and without COPD.
Reproducibility of EBC biomarkers 
in smokers
We assessed the reproducibility of EBC biomarkers using 
the Bland-Altman method, which calculates the limits of 
agreement (ie, the range of variation that can be expected 
for repeated measurements from the same subject) (Bland 
and Altman 1986). This is the ﬁ  rst report of the variability 
of EBC pH, 8-isoprostane and LTB4 in smokers. Overall, 
our results for all measurements demonstrated only small 
changes in group mean differences over 1 week. However, 
the variability between individual measurements (determined 
by the limits of agreement) may be relatively large. Using 
limits of agreement, we have recently shown considerable 
within subject variability of EBC 8 isoprostane and LTB4 
in COPD patients (Borrill et al 2007) and of EBC pH from 
COPD patients compared to healthy controls (Borrill et al 
2005). We believe that this increased variability compared to 
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Figure 5 (A) Pearson’s correlation in smokers between natural log (Ln) exhaled breath condensate 8-isoprostane and LTB4 (n = 18). (B) Spearman’s correlation in smok-
ers between sputum supernatant IL-8 (pg/ml) and EBC pH (n = 15). (C) Pearson’s correlation in smokers between sputum supernatant IL-8 (pg/ml) and natural log (Ln) 
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that observed in healthy subjects is due to greater changes in 
airway inﬂ  ammation over time in COPD patients. Similarly, 
the results in the current study suggest that these changes in 
airway inﬂ  ammation over time also occur in smokers.
Although the current study used a relatively small 
sample size, we were still able to adequately assess the 
reproducibility of the EBC biomarkers. For 8-isoprostane 
and LTB4, the poor reproducibility contributes to the reduced 
sensitivity of these measurements in small sample sizes. 
However, despite these issues, this study still provides some 
novel insights into the effects of smoking on the airways.
Correlations in smokers
There was a strong correlation between exhaled breath con-
densate LTB4 and 8-isoprostane in smokers. However, there 
were no signiﬁ  cant correlations between these 2 biomarkers 
and EBC pH. Similarly, it has been shown in COPD patients 
that EBC pH and 8-isoprostane are not related (Kostikas 
et al 2003). While pH did not relate to other EBC measure-
ments, there was a signiﬁ  cant correlation between EBC pH 
and sputum supernatant IL-8, a potent neutrophil chemoat-
tractant. This suggests that airway acidiﬁ  cation is related 
to neutrophilic inﬂ  ux in smokers. Indeed in COPD patients 
a similar relationship was observed between EBC pH and 
sputum neutrophilia (Kostikas et al 2002), although in our 
study this relationship failed to reach statistical signiﬁ  cance. 
Our observation of a signiﬁ  cant correlation between sputum 
supernatant IL-8 and both total cell count and total neutrophil 
count are in agreement with a previous study (Chalmers 
et al 2001).
Conclusion
The pathological processes of airway inﬂ  ammation and 
oxidative stress were demonstrated in smokers using non-
invasive biomarkers. The positive relationship observed 
between sputum IL-8 and EBC pH suggests that airway 
acidity is related to neutrophilic inﬂ  ammation. Therefore, 
these techniques may be useful in the early detection of 
cigarette smoke-induced pathophysiological abnormali-
ties. However, our EBC reproducibility data adds to the 
growing body of evidence indicating that the sensitivity 
and reproducibility of 8 isoprostane and LTB4 assays need 
to be improved.
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